Loading articles...
Patients on lorlatinib should be monitored for hyperglycemia, regardless of autoantibody status. This case raises concerns about potential metabolic toxicities of ALK inhibitors beyond what is currently recognized.
The VICTORION-PLAQUE trial in primary prevention evaluates inclisiran, a small interfering RNA targeting PCSK9, for effects on atherosclerotic plaque using prespecified multimodality imaging endpoints. Randomized and double-blind, with dosing at day 1, day ...